DURECT Corporation (DRRX)
USD 0.6
(3.1%)
USD 0.6
(3.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.65 Million USD | 62.15% |
| 2022 | -20.22 Million USD | 20.83% |
| 2021 | -25.54 Million USD | -666.93% |
| 2020 | 4.5 Million USD | 155.6% |
| 2019 | -8.1 Million USD | 27.08% |
| 2018 | -11.11 Million USD | -17.45% |
| 2017 | -9.46 Million USD | -113.26% |
| 2016 | -4.43 Million USD | -127.55% |
| 2015 | 16.1 Million USD | -6.08% |
| 2014 | 17.14 Million USD | 318.79% |
| 2013 | -7.83 Million USD | 30.0% |
| 2012 | -11.19 Million USD | -25.84% |
| 2011 | -8.89 Million USD | 14.76% |
| 2010 | -10.43 Million USD | -34.17% |
| 2009 | -7.77 Million USD | 72.98% |
| 2008 | -28.78 Million USD | -113.13% |
| 2007 | -13.5 Million USD | -301.19% |
| 2006 | -3.36 Million USD | -245.69% |
| 2005 | -974 Thousand USD | -102.35% |
| 2004 | 41.38 Million USD | 1.86% |
| 2003 | 40.63 Million USD | 436.0% |
| 2002 | -12.09 Million USD | -21.94% |
| 2001 | -9.91 Million USD | 78.05% |
| 2000 | -45.19 Million USD | -1176.19% |
| 1999 | -3.54 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 418 Thousand USD | 147.72% |
| 2024 Q1 | -876 Thousand USD | 88.56% |
| 2023 Q2 | -8.91 Million USD | 45.45% |
| 2023 Q1 | -16.33 Million USD | 19.2% |
| 2023 Q4 | -7.65 Million USD | 51.65% |
| 2023 FY | -7.65 Million USD | 62.15% |
| 2023 Q3 | -15.83 Million USD | -77.64% |
| 2022 FY | -20.22 Million USD | 20.83% |
| 2022 Q1 | -25.37 Million USD | 0.66% |
| 2022 Q3 | -26.84 Million USD | -15.13% |
| 2022 Q2 | -23.32 Million USD | 8.08% |
| 2022 Q4 | -20.22 Million USD | 24.69% |
| 2021 Q1 | -31.89 Million USD | -808.08% |
| 2021 FY | -25.54 Million USD | -666.93% |
| 2021 Q4 | -25.54 Million USD | 17.32% |
| 2021 Q2 | -31.35 Million USD | 1.72% |
| 2021 Q3 | -30.89 Million USD | 1.46% |
| 2020 Q3 | 7.55 Million USD | -5.47% |
| 2020 Q1 | -5.93 Million USD | 26.72% |
| 2020 FY | 4.5 Million USD | 155.6% |
| 2020 Q4 | 4.5 Million USD | -40.38% |
| 2020 Q2 | 7.99 Million USD | 234.63% |
| 2019 Q4 | -8.1 Million USD | 31.98% |
| 2019 Q2 | -8.97 Million USD | -2017.95% |
| 2019 Q1 | 468 Thousand USD | 104.21% |
| 2019 Q3 | -11.91 Million USD | -32.7% |
| 2019 FY | -8.1 Million USD | 27.08% |
| 2018 Q3 | -18.32 Million USD | -4.86% |
| 2018 FY | -11.11 Million USD | -17.45% |
| 2018 Q1 | -19.49 Million USD | -106.05% |
| 2018 Q2 | -17.47 Million USD | 10.34% |
| 2018 Q4 | -11.11 Million USD | 39.37% |
| 2017 Q2 | -10.52 Million USD | -167.46% |
| 2017 Q1 | 15.59 Million USD | 451.6% |
| 2017 FY | -9.46 Million USD | -113.26% |
| 2017 Q3 | -15.38 Million USD | -46.26% |
| 2017 Q4 | -9.46 Million USD | 38.52% |
| 2016 Q3 | 14.47 Million USD | 23.55% |
| 2016 Q1 | 15.86 Million USD | -1.47% |
| 2016 Q2 | 11.71 Million USD | -26.15% |
| 2016 Q4 | -4.43 Million USD | -130.65% |
| 2016 FY | -4.43 Million USD | -127.55% |
| 2015 Q3 | 14.26 Million USD | 2.8% |
| 2015 Q4 | 16.1 Million USD | 12.9% |
| 2015 FY | 16.1 Million USD | -6.08% |
| 2015 Q1 | 17.85 Million USD | 4.14% |
| 2015 Q2 | 13.87 Million USD | -22.3% |
| 2014 Q1 | -1.97 Million USD | 74.86% |
| 2014 Q2 | 1.11 Million USD | 156.45% |
| 2014 FY | 17.14 Million USD | 318.79% |
| 2014 Q3 | 16.38 Million USD | 1373.38% |
| 2014 Q4 | 17.14 Million USD | 4.64% |
| 2013 FY | -7.83 Million USD | 30.0% |
| 2013 Q4 | -7.83 Million USD | 18.02% |
| 2013 Q3 | -9.55 Million USD | -19.64% |
| 2013 Q1 | -8.25 Million USD | 26.31% |
| 2013 Q2 | -7.98 Million USD | 3.16% |
| 2012 Q1 | -7.53 Million USD | 15.28% |
| 2012 Q2 | -4.15 Million USD | 44.86% |
| 2012 FY | -11.19 Million USD | -25.84% |
| 2012 Q4 | -11.19 Million USD | -78.12% |
| 2012 Q3 | -6.28 Million USD | -51.23% |
| 2011 Q3 | -7.03 Million USD | -28.16% |
| 2011 FY | -8.89 Million USD | 14.76% |
| 2011 Q4 | -8.89 Million USD | -26.53% |
| 2011 Q2 | -5.48 Million USD | -13.58% |
| 2011 Q1 | -4.83 Million USD | 53.72% |
| 2010 Q3 | -12.13 Million USD | 42.94% |
| 2010 FY | -10.43 Million USD | -34.17% |
| 2010 Q2 | -21.27 Million USD | -502.81% |
| 2010 Q4 | -10.43 Million USD | 14.01% |
| 2010 Q1 | -3.52 Million USD | 54.63% |
| 2009 Q4 | -7.77 Million USD | 56.62% |
| 2009 FY | -7.77 Million USD | 72.98% |
| 2009 Q1 | -22.79 Million USD | 20.82% |
| 2009 Q2 | -9.41 Million USD | 58.72% |
| 2009 Q3 | -17.93 Million USD | -90.57% |
| 2008 Q1 | -10.31 Million USD | 23.65% |
| 2008 Q3 | -23.08 Million USD | 26.59% |
| 2008 Q2 | -31.44 Million USD | -204.88% |
| 2008 FY | -28.78 Million USD | -113.13% |
| 2008 Q4 | -28.78 Million USD | -24.71% |
| 2007 Q2 | 5.87 Million USD | 22.64% |
| 2007 FY | -13.5 Million USD | -301.19% |
| 2007 Q4 | -13.5 Million USD | -555.73% |
| 2007 Q1 | 4.79 Million USD | 242.35% |
| 2007 Q3 | -2.06 Million USD | -135.05% |
| 2006 Q4 | -3.36 Million USD | -597.34% |
| 2006 Q3 | 677 Thousand USD | 123.75% |
| 2006 Q2 | -2.85 Million USD | -119.97% |
| 2006 Q1 | 14.26 Million USD | 1564.99% |
| 2006 FY | -3.36 Million USD | -245.69% |
| 2005 Q2 | 38.74 Million USD | -9.63% |
| 2005 Q3 | 29.62 Million USD | -23.54% |
| 2005 Q4 | -974 Thousand USD | -103.29% |
| 2005 FY | -974 Thousand USD | -102.35% |
| 2005 Q1 | 42.87 Million USD | 3.59% |
| 2004 Q3 | 43.42 Million USD | -19.6% |
| 2004 Q4 | 41.38 Million USD | -4.7% |
| 2004 FY | 41.38 Million USD | 1.86% |
| 2004 Q1 | 40.09 Million USD | -1.32% |
| 2004 Q2 | 54.01 Million USD | 34.71% |
| 2003 Q1 | -13.99 Million USD | -15.72% |
| 2003 FY | 40.63 Million USD | 436.0% |
| 2003 Q2 | 15.3 Million USD | 209.38% |
| 2003 Q3 | -22.82 Million USD | -249.12% |
| 2003 Q4 | 40.63 Million USD | 278.01% |
| 2002 Q3 | -16.1 Million USD | -223.67% |
| 2002 Q4 | -12.09 Million USD | 24.93% |
| 2002 Q1 | -13.57 Million USD | -36.92% |
| 2002 Q2 | -4.97 Million USD | 63.35% |
| 2002 FY | -12.09 Million USD | -21.94% |
| 2001 FY | -9.91 Million USD | 78.05% |
| 2001 Q4 | -9.91 Million USD | 44.95% |
| 2001 Q3 | -18.01 Million USD | 44.67% |
| 2001 Q2 | -32.55 Million USD | 29.42% |
| 2001 Q1 | -46.12 Million USD | -2.07% |
| 2000 FY | -45.19 Million USD | -1176.19% |
| 2000 Q3 | -18.07 Million USD | 25.31% |
| 2000 Q4 | -45.19 Million USD | -150.07% |
| 2000 Q2 | -24.19 Million USD | 0.0% |
| 1999 FY | -3.54 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 108.125% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 110.212% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.758% |
| Cosmos Health Inc. | 8.59 Million USD | 189.096% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 6.812% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.669% |
| Cronos Group Inc. | -663.32 Million USD | 98.846% |
| Incannex Healthcare Limited | -5.48 Million USD | -39.544% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 47.475% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 106.279% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -163.801% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 51.045% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 51.045% |
| SCYNEXIS, Inc. | -19.35 Million USD | 60.444% |
| Safety Shot Inc | -2.28 Million USD | -235.059% |
| Theratechnologies Inc. | 24.87 Million USD | 130.775% |
| Alpha Teknova, Inc. | 1.97 Million USD | 487.741% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 3981.162% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.769% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -203.73% |
| Dynavax Technologies Corporation | 106.63 Million USD | 107.178% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 101.228% |
| Radius Health, Inc. | 359.28 Million USD | 102.13% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 18.831% |
| Alvotech | 1.06 Billion USD | 100.719% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 94.15% |
| SIGA Technologies, Inc. | -148.68 Million USD | 94.852% |
| Shineco, Inc. | 29.29 Million USD | 126.132% |
| Silver Spike Investment Corp. | -32.61 Million USD | 76.53% |
| Journey Medical Corporation | -9.7 Million USD | 21.166% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -51.253% |
| Embecta Corp. | 1.31 Billion USD | 100.583% |
| Harrow Health, Inc. | 116.41 Million USD | 106.575% |
| Procaps Group, S.A. | 242.93 Million USD | 103.151% |
| Biofrontera Inc. | 4.05 Million USD | 288.708% |
| PainReform Ltd. | -7.95 Million USD | 3.723% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 77.171% |
| OptiNose, Inc. | 58.06 Million USD | 113.182% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -47.589% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 150.982% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 7262.71% |
| ProPhase Labs, Inc. | 19.23 Million USD | 139.8% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.683% |
| Procaps Group S.A. | 242.93 Million USD | 103.151% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 308.102% |
| Viatris Inc. | 17.13 Billion USD | 100.045% |
| Rockwell Medical, Inc. | 4.45 Million USD | 271.768% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -56.941% |
| Tilray Brands, Inc. | 158.97 Million USD | 104.815% |
| PetIQ, Inc. | 351.93 Million USD | 102.175% |
| Talphera, Inc. | -5.72 Million USD | -33.788% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 104.317% |
| Alimera Sciences, Inc. | 55.3 Million USD | 113.839% |
| Assertio Holdings, Inc. | -32.52 Million USD | 76.47% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -414.132% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 281.503% |
| Hempacco Co., Inc. | 13.61 Million USD | 156.219% |
| Alvotech | 1.06 Billion USD | 100.719% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 92.086% |
| Kamada Ltd. | -46.43 Million USD | 83.516% |
| Currenc Group, Inc. | -16.57 Million USD | 53.817% |
| Indivior PLC | -33.95 Million USD | 77.456% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 3037.361% |
| Flora Growth Corp. | -713 Thousand USD | -973.492% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 6.812% |
| Evolus, Inc. | 63.7 Million USD | 112.014% |
| HUTCHMED (China) Limited | -197.45 Million USD | 96.124% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.598% |
| Akanda Corp. | 3.9 Million USD | 296.009% |